Cytori Therapeutics Inc. (NASDAQ:CYTX) shares were up 7.4% during mid-day trading on Friday . The company traded as high as $2.05 and last traded at $2.02, with a volume of 134,150 shares. The stock had previously closed at $1.88.

A number of research analysts recently issued reports on CYTX shares. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Cytori Therapeutics in a report on Wednesday, July 20th. Zacks Investment Research raised Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Tuesday, July 12th. Finally, Roth Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Cytori Therapeutics in a report on Tuesday, June 28th.

The company’s market cap is $42.01 million. The firm has a 50-day moving average price of $2.04 and a 200 day moving average price of $2.79.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.04. The company earned $1.10 million during the quarter, compared to analyst estimates of $2.50 million. Cytori Therapeutics’s quarterly revenue was down 31.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.06) earnings per share. Equities analysts expect that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.